UBS Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

UBS Group’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-82,933	Closed	-$4.47M	–	8498
2017 Q4	$4.47M	Sell	82,933 -126,855	-60%	-$6.94M	﹤0.01%	2462
2017 Q3	$12M	Buy	209,788 +67,736	+48%	+$3.97M	0.01%	1472
2017 Q2	$8.55M	Buy	142,052 +45,473	+47%	+$2.59M	﹤0.01%	1677
2017 Q1	$5.26M	Buy	+96,579	New	+$4.76M	﹤0.01%	2050

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

UBS Group's BIVV Position: Q1 2018 in Review

UBS Group sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 82,933 shares — an estimated $4.47M sold.

UBS Group first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $12M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

UBS Group reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
UBS Group sold 82,933 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $4.47M.
UBS Group first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
UBS Group's Bioverativ Inc. Common Stock position peaked at $12M in Q3 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.